Jay R. Luly Acquires 45,000 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly purchased 45,000 shares of the company’s stock in a transaction on Wednesday, February 12th. The shares were purchased at an average cost of $5.69 per share, with a total value of $256,050.00. Following the transaction, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock opened at $7.50 on Friday. The company has a 50-day moving average of $5.75 and a 200 day moving average of $9.51. The firm has a market cap of $159.98 million, a price-to-earnings ratio of -1.37 and a beta of 0.54. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.71 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. On average, equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ENTA. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday. Finally, Robert W. Baird dropped their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. AlphaQuest LLC increased its stake in shares of Enanta Pharmaceuticals by 16.4% in the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 3,137 shares in the last quarter. Invesco Ltd. increased its stake in Enanta Pharmaceuticals by 7.3% during the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 3,186 shares in the last quarter. American Century Companies Inc. increased its stake in Enanta Pharmaceuticals by 10.5% during the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 3,501 shares in the last quarter. US Bancorp DE increased its stake in Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Enanta Pharmaceuticals during the 4th quarter valued at about $26,000. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.